{
  "abstract": "Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO®), a humanised immunoglobulin G4P monoclonal antibody, is a subcutaneously administered neonatal Fc receptor (FcRn) inhibitor approved for the treatment of both acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) autoantibody-positive (Ab+) generalised myasthenia gravis (gMG) in adults. The pivotal, randomised, placebo-controlled phase III MycarinG trial demonstrated that a 6-week cycle of once-weekly rozanolixizumab ≈ 7 mg/kg or ≈ 10 mg/kg resulted in statistically significant and clinically meaningful improvements across all myasthenia gravis-specific scales assessed at day 43 versus placebo. Treatment benefits were rapid, sustained and consistent across repeated symptom-driven rozanolixizumab cycles. In a randomised, open-label, phase III crossover trial, self-administered rozanolixizumab improved MG symptoms regardless of whether manual push or infusion pump method was used. Rozanolixizumab was generally well tolerated with an acceptable safety profile; the most common adverse events were headache, diarrhoea, pyrexia and nausea. Thus, rozanolixizumab is an efficacious and generally well tolerated therapy for adults with AChR or MuSK Ab+ gMG, representing a convenient and valuable additional treatment option for these patients.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40263-026-01335-3.",
  "abstract_shown": true,
  "affiliations": [
    "Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754 New Zealand"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Aisling McGuigan",
      "orcid": "0009-0009-7260-8131"
    },
    {
      "affs": [
        0
      ],
      "name": "Hannah A. Blair"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/azd210q64ergm.bib",
  "cited_by": 0,
  "doi": "10.1007/s40263-026-01335-3",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13719728/",
  "id": "azd210q64ergm",
  "issns": [
    "1172-7047",
    "1179-1934"
  ],
  "landing_url": "https://doi.org/10.1007/s40263-026-01335-3",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Adis Drug Evaluation"
    ],
    [
      "openalex",
      "2728|Myasthenia Gravis and Thymoma"
    ]
  ],
  "openalex": "W7213913719",
  "pdf_url": null,
  "pmcid": "PMC13719728",
  "pmid": "42814271",
  "published": "2026-09-30",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/azd210q64ergm.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T12:23:38Z",
      "native_id": "PMC13719728",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s40263-026-01335-3"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Myasthenia Gravis and Thymoma",
      "subfield": "neurology"
    }
  ],
  "title": "Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis",
  "title_text": "Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:20:44Z",
  "url": "https://research.draconitic.com/paper/azd210q64ergm",
  "venue": "CNS Drugs",
  "versions": []
}